✦ LIBER ✦

A Comparative, Randomized Trial of Concentration-Controlled Sirolimus Combined With Reduced-Dose Tacrolimus or Standard-Dose Tacrolimus in Renal Allograft Recipients

✍ Scribed by Bechstein, W.O.; Paczek, L.; Wramner, L.; Squifflet, J.-P.; Zygmunt, A.J.

Book ID: 122351781
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 542 KB
Volume: 45
Category: Article
ISSN: 0041-1345
DOI: 10.1016/j.transproceed.2013.03.025

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics, efficacy, and safety o

Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients

✍ Björn Nashan; Faouzi Saliba; Francois Durand; Rafael Barcéna; Jose Ignacio Herre 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 455 KB 👁 1 views

The pharmacokinetics of mycophenolate mofetil (MMF) in liver transplant recipients may change because of pharmacokinetic interactions with coadministered immunosuppressants or because changes in the enterohepatic anatomy may affect biotransformation of MMF to mycophenolic acid (MPA) and enterohepati

Evaluation of renal function in liver tr

Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial

✍ Eric M. Yoshida; Paul J. Marotta; Paul D. Greig; Norman M. Kneteman; Denis Marle 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

Posttransplant chronic renal failure, secondary to calcineurin inhibitor agents, is emerging as a major problem in liver transplantation. We report a randomized clinical trial comparing daclizumab, delayed low-dose tacrolimus (target trough level 4-8 ng/mL, starting day 4-6), Investigational Arm (n